Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
11.15
-0.66 (-5.59%)
At close: Aug 1, 2025, 4:00 PM
11.24
+0.09 (0.81%)
After-hours: Aug 1, 2025, 4:33 PM EDT
Patterson Companies Employees
Lyell Immunopharma had 300 employees as of December 31, 2024. The number of employees increased by 76 or 33.93% compared to the previous year.
Employees
300
Change (1Y)
76
Growth (1Y)
33.93%
Revenue / Employee
$217
Profits / Employee
-$1,115,073
Market Cap
165.36M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 300 | 76 | 33.93% |
| Dec 31, 2023 | 224 | -50 | -18.25% |
| Dec 31, 2022 | 274 | 55 | 25.11% |
| Dec 31, 2021 | 219 | 29 | 15.26% |
| Dec 31, 2020 | 190 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LYEL News
- 7 days ago - Lyell Immunopharma Announces up to $100 Million Equity Private Placement - GlobeNewsWire
- 10 days ago - Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement - Seeking Alpha
- 5 weeks ago - Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewsWire
- 6 weeks ago - Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma - GlobeNewsWire
- 7 weeks ago - Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewsWire
- 2 months ago - Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 - GlobeNewsWire